References
- Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention (2018 update). Available from: www.ginasthma.org [last accessed 24 September 2018].
- Centers for Disease Control and Prevention. Most recent asthma data 2018 (updated May 2018). Available from: https://www.cdc.gov/asthma/most_recent_data.htm [last accessed 8 November 2018].
- GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5:691–706. doi:https://doi.org/10.1016/s2213-2600(17)30293-x.
- Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009. doi:https://doi.org/10.1038/npjpcrm.2014.9.
- Braido F, Brusselle G, Guastalla D, Ingrassia E, Nicolini G, Price D, Roche N, Soriano JB, Worth H, LIAISON Study Group. Determinants and impact of suboptimal asthma control in Europe: the international cross-sectional and longitudinal assessment on asthma control (LIAISON) study. Respir Res. 2016;17(1):51. doi:https://doi.org/10.1186/s12931-016-0374-z.
- Lee LK, Obi E, Paknis B, Kavati A, Chipps B. Asthma control and disease burden in patients with asthma and allergic comorbidities. J Asthma. 2018;55(2):208–219. doi:https://doi.org/10.1080/02770903.2017.1316394.
- Ban GY, Ye YM, Lee Y, Kim JE, Nam YH, Lee SK, Kim JH, Jung KS, Kim SH, Park HS. Predictors of asthma control by stepwise treatment in elderly asthmatic patients. J Korean Med Sci. 2015;30(8):1042–1047. doi:https://doi.org/10.3346/jkms.2015.30.8.1042.
- Tay TR, Wong HS, Tee A. Predictors of future exacerbations in a multi-ethnic Asian population with asthma. J Asthma. 2019;56:380–387. doi:https://doi.org/10.1080/02770903.2018.1458862.
- Bloom CI, Nissen F, Douglas IJ, Smeeth L, Cullinan P, Quint JK. Exacerbation risk and characterisation of the UK’s asthma population from infants to old age. Thorax. 2018;73(4):313–320. doi:https://doi.org/10.1136/thoraxjnl-2017-210650.
- Castillo JR, Peters SP, Busse WW. Asthma exacerbations: pathogenesis, prevention, and treatment. J Allergy Clin Immunol Pract. 2017;5(4):918–927. doi:https://doi.org/10.1016/j.jaip.2017.05.001.
- King GG, James A, Harkness L, Wark PAB. Pathophysiology of severe asthma: we’ve only just started. Respirology. 2018;23(3):262–271. doi:https://doi.org/10.1111/resp.13251.
- Matsunaga K, Hirano T, Oka A, Tanaka A, Kanai K, Kikuchi T, Hayata A, Akamatsu H, Akamatsu K, Koh Y, et al. Progression of irreversible airflow limitation in asthma: correlation with severe exacerbations. J Allergy Clin Immunol Pract. 2015;3(5):759–764.e1. doi:https://doi.org/10.1016/j.jaip.2015.05.005.
- Quezada W, Kwak ES, Reibman J, Rogers L, Mastronarde J, Teague WG, Wei C, Holbrook JT, DiMango E. Predictors of asthma exacerbation among patients with poorly controlled asthma despite inhaled corticosteroid treatment. Ann Allergy Asthma Immunol. 2016;116(2):112–117. doi:https://doi.org/10.1016/j.anai.2015.11.011.
- Suruki RY, Daugherty JB, Boudiaf N, Albers FC. The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA. BMC Pulm Med. 2017;17(1):74. doi:https://doi.org/10.1186/s12890-017-0409-3.
- Sicras-Mainar A, Capel M, Navarro-Artieda R, Nuevo J, Orellana M, Resler G. Real-life retrospective observational study to determine the prevalence and economic burden of severe asthma in Spain. J Med Econ. 2020;23(5):492–500. doi:https://doi.org/10.1080/13696998.2020.1719118.
- de Groot EP, Kreggemeijer WJ, Brand PL. Getting the basics right resolves most cases of uncontrolled and problematic asthma. Acta Paediatr. 2015;104(9):916–921. doi:https://doi.org/10.1111/apa.13059.
- Sullivan PW, Ghushchyan V, Navaratnam P, Friedman HS, Kavati A, Ortiz B, Lanier B. National prevalence of poor asthma control and associated outcomes among school-aged children in the United States. J Allergy Clin Immunol Pract. 2018;6(2):536–544.e1. doi:https://doi.org/10.1016/j.jaip.2017.06.039.
- Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention (2017 update). Available from: www.ginasthma.org [last accessed 2 April 2019].
- Broder MS, Chang EY, Kamath T, Sapra S. Poor disease control among insured users of high-dose combination therapy for asthma. Allergy Asthma Proc. 2010;31(1):60–67. doi:https://doi.org/10.2500/aap.2010.31.3302.
- International Society of Pharmacoepidemiology: Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Safety. 2008;17:200–208. doi:https://doi.org/10.1002/pds.1471.
- von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–349. doi:https://doi.org/10.1016/j.jclinepi.2007.11.008.
- Buhl R, Heaney LG, Loefroth E, Larbig M, Kostikas K, Conti V, Cao H. One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting β2-agonist in UK primary care settings. Respir Med. 2020;162:105859. doi:https://doi.org/10.1016/j.rmed.2019.105859.
- FitzGerald JM, Barnes PJ, Chipps BE, Jenkins CR, O’Byrne PM, Pavord ID, Reddel HK. The burden of exacerbations in mild asthma: a systematic review. ERJ Open Res. 2020;6(3):00359-2019. doi:https://doi.org/10.1183/23120541.
- Baptist AP, Hao W, Song PX, Carpenter L, Steinberg J, Cardozo LJ. A behavioral intervention can decrease asthma exacerbations in older adults. Ann Allergy Asthma Immunol. 2020;124(3):248–253.e3. doi:https://doi.org/10.1016/j.anai.2019.12.015.
- Kankaanranta H, Kauppi P, Tuomisto LE, Ilmarinen P. Emerging comorbidities in adult asthma: risks, clinical associations, and mechanisms. Mediators Inflamm. 2016;2016:3690628. doi:https://doi.org/10.1155/2016/3690628.
- Bardin PG, Rangaswamy J, Yo SW. Managing comorbid conditions in severe asthma. Med J Aust. 2018;209(S2):S11–S17. doi:https://doi.org/10.5694/mja18.00196.
- Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MC, Verhamme KM. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2015;45(2):396–407. doi:https://doi.org/10.1183/09031936.00075614.
- Normansell R, Kew KM, Stovold E. Interventions to improve adherence to inhaled steroids for asthma. Cochrane Database Syst Rev. 2017;4:CD012226. doi:https://doi.org/10.1002/14651858.CD012226.pub2.
- Arora P, Kumar L, Vohra V, Sarin R, Jaiswal A, Puri MM, Rathee D, Chakraborty P. Evaluating the technique of using inhalation device in COPD and bronchial asthma patients. Respir Med. 2014;108(7):992–998. doi:https://doi.org/10.1016/j.rmed.2014.04.021.
- Roman-Rodriguez M, Metting E, Gacia-Pardo M, Kocks J, van der Molen T. Wrong inhalation technique is associated to poor asthma clinical outcomes. Is there room for improvement? Curr Opin Pulm Med. 2019;25(1):18–26. doi:https://doi.org/10.1097/mcp.0000000000000540.
- Boulet LP, Boulay ME, Gauthier G, Battisti L, Chabot V, Beauchesne MF, Villeneuve D, Cote P. Benefits of an asthma education program provided at primary care sites on asthma outcomes. Respir Med. 2015;109(8):991–1000. doi:https://doi.org/10.1016/j.rmed.2015.05.004.
- Herman E, Beavers S, Hamlin B, Thaker K. Is it time for a patient-centered quality measure of asthma control?J Allergy Clin Immunol Pract. 2019;7(6):1771–1777. doi:https://doi.org/10.1016/j.jaip.2019.02.016.
- Arellano FM, Arana A, Wentworth CE, Vidaurre CF, Chipps BE. Prescription patterns for asthma medications in children and adolescents with health care insurance in the United States. Pediatr Allergy Immunol. 2011;22(5):469–476. doi:https://doi.org/10.1111/j.1399-3038.2010.01121.x.
- Butler MG, Zhou EH, Zhang F, Wu YT, Wu AC, Levenson MS, Wu P, Seymour S, Toh S, Iyer A, et al. Changing patterns of asthma medication use related to US Food and Drug Administration long-acting β2-agonist regulation from 2005-2011. J Allergy Clin Immunol. 2016;137(3):710–717. doi:https://doi.org/10.1016/j.jaci.2015.09.057.
- Llanos JP, Bell CF, Packnett E, Thiel E, Irwin DE, Hahn B, Ortega H. Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study. J Asthma Allergy. 2019;12:43–58. doi:https://doi.org/10.2147/JAA.S189676.
- Korelitz JJ, Zito JM, Gavin NI, Masters MN, McNally D, Irwin DE, Kelleher K, Bethel J, Xu Y, Rubin J, et al. Asthma-related medication use among children in the United States. Ann Allergy Asthma Immunol. 2008;100(3):222–229. doi:https://doi.org/10.1016/s1081-1206(10)60446-2.
- Lagos JA, Marshall GD. Montelukast in the management of allergic rhinitis. Ther Clin Risk Manag. 2007;3(2):327–332. doi:https://doi.org/10.2147/tcrm.2007.3.2.327.
- Dusser D, Montani D, Chanez P, de Blic J, Delacourt C, Deschildre A, Devillier P, Didier A, Leroyer C, Marguet C, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy. 2007;62(6):591–604. doi:https://doi.org/10.1111/j.1398-9995.2007.01394.x.
- Reddel HK, Busse WW, Pedersen S, Tan WC, Chen YZ, Jorup C, Lythgoe D, O’Byrne PM. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet. 2017;389(10065):157–166. doi:https://doi.org/10.1016/S0140-6736(16)31399-X.
- Battaglia S, Benfante A, Spatafora M, Scichilone N. Asthma in the elderly: a different disease?Breathe (Sheff). 2016;12(1):18–28. doi:https://doi.org/10.1183/20734735.002816.
- Wardzyńska A, Kubsik B, Kowalski ML. Comorbidities in elderly patients with asthma: association with control of the disease and concomitant treatment. Geriatr Gerontol Int. 2015;15(7):902–909. doi:https://doi.org/10.1111/ggi.12367.
- Gibson PG. Variability of blood eosinophils as a biomarker in asthma and COPD. Respirology. 2018;23(1):12–13. doi:https://doi.org/10.1111/resp.13200.
- Lababidi HM, AlSowayigh OM, BinHowemel SF, AlReshaid KM, Alotaiq SA, Bahnassay AA. Refractory asthma phenotyping based on immunoglobulin E levels and eosinophilic counts: a real life study. Respir Med. 2019;158:55–58. doi:https://doi.org/10.1016/j.rmed.2019.10.003.
- Bostantzoglou C, Delimpoura V, Samitas K, Zervas E, Kanniess F, Gaga M. Clinical asthma phenotypes in the real world: opportunities and challenges. Breathe (Sheff). 2015;11(3):186–193. doi:https://doi.org/10.1183/20734735.008115.
- Izquierdo-Dominguez A, Jauregui I, Del Cuvillo A, Montoro J, Davila I, Sastre J, Bartra J, Ferrer M, Alobid I, Mullol J, et al. Allergy rhinitis: similarities and differences between children and adults. Rhinology. 2017;55(4):326–331. doi:https://doi.org/10.4193/Rhin17.074.
- Chapman KR, Hinds D, Piazza P, Raherison C, Gibbs M, Greulich T, Gaalswyk K, Lin J, Adachi M, Davis KJ. Physician perspectives on the burden and management of asthma in six countries: the Global Asthma Physician Survey (GAPS). BMC Pulm Med. 2017;17(1):153. doi:https://doi.org/10.1186/s12890-017-0492-5.
- Hew M, Reddel HK. Integrated adherence monitoring for inhaler medications. JAMA. 2019;321(11):1045–1046. doi:https://doi.org/10.1001/jama.2019.1289.
- Wachter RM, Judson TJ, Mourad M. Reimagining specialty consultation in the digital age: the potential role of targeted automatic electronic consultations. JAMA. 2019;322(5):399. doi:https://doi.org/10.1001/jama.2019.6607.
- Chipps BE, Lanier B, Milgrom H, Deschildre A, Hedlin G, Szefler SJ, Kattan M, Kianifard F, Ortiz B, Haselkorn T, et al. Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. J Allergy Clin Immunol. 2017;139(5):1431–1444. doi:https://doi.org/10.1016/j.jaci.2017.03.002.